Saturday, Nov. 1, 2014

Health News

The Illusive Magic Bullet?

CIHR announces major AIDS breakthrough

Released by HIV Net UBC

 

n ANRS and CTN study shows ‘on-demand’ pre-exposure prophylaxis (PrEP) taken before sex reduces risk for HIV among men who have sex with men.

 

“This study extends the versatility of PrEP for real-world conditions and adds another prevention tool along with counseling and condoms,” says Dr. Cécile Tremblay, the Canadian Principal Investigator of CTN 268.

 

Unlike other studies that tested the daily use of PrEP, ANRS IPERGAY tested the intermittent or ‘on demand’ use of Truvada. Participants randomized to the treatment arm, took two pills in the 24-hour period before anticipated sexual intercourse and two separate one-pill doses in the two days following sex. 
 
The ANRS IPERGAY trial was run by the French national AIDS research institute, ANRS, and began in France in February 2012 with the Professor Jean-Michel Molina as the Principal Investigator. The CIHR Canadian HIV Trials Network (CTN) joined as a Canadian site in 2013 and was led by Dr. Cécile Tremblay (Centre hospitalier de l’Université de Montréal (CHUM). In Canada, the study recruited 53 men who have sex with men (MSM) into Phase I of the randomized study.
 
Following recent results of other studies (PROUD and iPrEx) recommending the daily use of PrEP, the ANRS contacted the IPERGAY trial data safety monitoring board (DSMB) for a review. The DSMB examined the unblinded data and found a significant difference in incidence between the treatment and placebo group with a “very significant reduction” in the risk of HIV infection in the PrEP group. The DSMB therefore recommended that all IPERGAY participants should be offered ‘on demand’ Truvada.
 
The full results of the ANRS IPERGAY trial will be available in early 2015. The study will continue with open-abel ‘on-demand’ Truvada for at least a year. It is important to ensure the continued long-term benefit of ‘on demand’ PrEP and also assess its long-term safety.
 
"The results of the ANRS IPERGAY trial will change prevention guidelines,” says Dr. Aslam Anis, CTN National Director.

 

 

About the CIHR Canadian HIV Trials Network:
The CIHR Canadian HIV Trials Network (CTN) is funded by the Canadian Institutes of Health Research (CIHR) and sponsored by the University of British Columbia and St. Paul’s Hospital (Providence Health Care). The CTN is a partnership of clinical investigators, physicians, nurses, people living with HIV, pharmaceutical manufacturers and others committed to developing treatments, vaccines and a cure for HIV and related conditions through the conduct of scientifically sound and ethical clinical trials. The CTN is committed to the pursuits of scientific excellence and ethical integrity in all undertakings. We are also dedicated to working in partnership with the international and national pharmaceutical industry, people living with HIV, researchers and physicians. www.hivnet.ubc.ca

 

 

© Copyright (c) 2009-2014 The Valley Voice